

Kintara (NASDAQ/KTRA)

August 17, 2021

BUY: GCAR Update - 26 Sites Enrolling Now

Kintara announced that the VAL-083 treatment arm of the GCAR (Global Coalition for Adaptive Research) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated in 26 U.S. sites.

Jason H. Kolbert

Senior Healthcare Analyst

646-465-6891

jkolbert@dawsonjames.com

Investment Highlights

The Phase 2 trial is an open-label, two-arm, biomarker-driven study evaluating VAL-083 in GBM patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene. Results show:


- Median overall survival (mOS) for the 48 efficacy evaluable patients initially receiving the treatment dose of 30 mg/m²/day is 8.0 months (95% confidence interval: CI 5.9-9.9 months). While this is not a head-to-head trial, historically, lomustine, which is the most commonly used chemotherapy for these patients, has demonstrated mOS of 7.2 months.
- Consistent with prior studies, myelosuppression was the most common adverse event. In the 30 mg/m²/day starting dose cohort, five patients experienced a serious adverse event (SAE) possibly related to VAL-083.
- For the 83 efficacy evaluable patients who have completed at least one cycle of treatment, mOS was 7.5 months (CI 6.1-9.0 months).

VAL-083 - The Trifecta. Kintara's VAL-083 is the only compound in the study that is going to be evaluated in all three major cancer types: 1. newly diagnosed unmethylated (NDUM), 2. recurrent GBM, and 3. newly diagnosed methylated MGMT (the first compound under evaluation for this cancer).

The Global Coalition for Adaptive Research, or GCAR Adaptive Study. The study plans to enroll 150-200 patients in each arm, so with control, this is an 800-plus patient study: three arms, three sponsors, plus control. Each company will evaluate its respective therapeutic, but only VAL-083 will be evaluated in three active arms. Futility will be evaluated at n=50, 100 and 150 patients, and efficacy will be evaluated at n=100 and 150 patients before the adaptive design transitions to pivotal phase.

Valuation. Our valuation is driven by our revenue projections for VAL-083 (GBM) and REM-001 for CMBC. For both indications, we apply a risk cut in our model (50%), which flows into our income statement. We model both products out to 2030. Our models also factor in the increase in shares from the merger as well as future assumed dilution, based on a projected, fully diluted 2030 share count. We triangulate FCFF, discounted EPS, and sum-of-the-parts models. We then average and equally weight each model to derive an NPV, which is rounded to the nearest whole number to calculate our price target.

Current Price	\$1.49
Price Target	\$5.00



Source: Kintara

Stock Data			
52-Week Range	\$1.03	-	\$3.35
Shares Outstanding (mil.)	32.6		
Market Capitalization (mil.)	\$49		
Enterprise Value (mil.)	\$41		
Debt to Capital	0%		
Book Value/Share	\$0.11		
Price/Book	14		
Average Three Months Trading Volume (K)	140		
Insider Ownership	15.8%		
Institutional Ownership	9.0%		
Short interest (mil.)	3.9%		
Dividend / Yield	\$0.00/0.0%		



Risk Analysis

Clinical and regulatory risk. Kintara Therapeutics is currently in Phase 2 clinical trials in both applications of its pipeline product focused on MGMT-unmethylated GBM. There is no assurance that its product will be approved for any additional indications and, even if approved, will be reimbursed by insurance or successfully commercialized.

Commercial risk. The focus of the Company is on successfully developing its products and eventually bringing them to the mass market. It is important to note that the market opportunity in MGMT-unmethylated GMB is large, and if successful, VAL-083 may be introduced to the market for multiple cancer applications. We can make no assurances that the Company will be able to achieve a critical level of market share to become profitable in this indication and/or in additional planned indications.

Employee risk. Kintara Therapeutics has an experienced management team in its President and CEO, CSO, and CFO. Kintara Therapeutics plans to bring its proposed products to reality. Kintara Therapeutics's success will depend, to a great extent, upon the experience, abilities and continued services of its senior officers, sales staff, and key scientific personnel.

Financial risk. The Company may need to raise capital in the marketplace relatively soon, and there can be no assurances that the Company will be able to raise capital and do so on favorable terms successfully.

Intellectual property risk. The Company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and the Company may infringe on third parties' patents.

Reimbursement and insurance payment risk. Insurance payment for products may be an additional hurdle for adoption.


Exhibit 1. Income Statement

Kintara Pharmaceuticals Inc. (KTRA): Income Statement ('000)	6. 2018 YE	6. 2019 A	6. 2020A	1Q21A	2Q21A	3Q21E	4Q21E	6. 2021 YE	6. 2022 YE	6. 2023 YE	6. 2024 YE	6. 2025 YE	6. 2026 YE	6. 2027 YE	6. 2028 YE	6. 2029 YE	6. 2030 YE
FYE-Jun 30	6.2018	6.2019 A	6.2020A	3Q20A	4Q20A	1Q21E	2Q21E	6.2021	6.2022	6.2023	6.2024	6.2025	6.2026	6.2027	6.2028	6.2029	6.2030
Revenue (\$000)																	
REM-001								0		23,394	82,779	119,558	132,961	146,646	172,971	187,366	202,057
VAL-083 U.S.										0	48,601	196,347	347,043	500,733	556,315	572,094	348,237
VAL-083 ROW										15,889	50,470	132,093	235,213	273,283	298,892	330,732	356,340
License Fees and Royalties (China sales)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Product Sales	-	-	-	-	-	-	-	-	-	39,282	181,849	447,998	715,217	920,663	1,028,177	1,090,191	906,635
Total Revenue	-	-	-	-	-	-	-	-	-	39,282	181,849	447,998	715,217	920,663	1,028,177	1,090,191	906,635
Expenses																	
Cost of Goods Sold	-	-	-	-	-	-	-	-	-	3,928	18,185	44,800	71,522	92,066	102,818	109,019	90,664
COGS % of revenue				10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
Sales, General and administrative expenses	4,042	4,736	4,515	1,534	2,762	1,140	1,186	4,560	5,000	5,050	10,000	10,100	10,201	10,303	10,406	10,510	10,615
SG&A % of revenue																	
Research and Development	7,133	3,662	4,684	1,357	3,843	1,183	1,230	4,731	7,000	9,000	12,000	12,120	12,241	12,364	12,487	12,612	12,738
R&D % of revenue																	
Non-GAAP, Adj				16594				16594									
Total expenses	11,175	8,398	9,198	19,485	6,605	2,323	2,415	30,828	12,000	17,978	35,031	64,362	91,280	112,022	122,973	129,376	111,224
Oper. Inc. (Loss)	(11,175)	(8,398)	(9,198)	(19,485)	(6,605)	(2,323)	(2,415)	(30,828)	(12,000)	21,304	146,818	383,636	623,938	808,641	905,205	960,816	795,411
Change in fair value of derivative liability	60	(434)	-					-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability due to change in warrant terms		126															
Issuance of shares to Valent																	
Loss on exchange of warrants																	
Foreign exchange gain	(57)	18	3	(1)	1			-	-	-	-	-	-	-	-	-	-
Interest expense	-	-	(75)	27	23			50	-	-	-	-	-	-	-	-	-
Interest income	33	(61)	-	8	7			15	-	-	-	-	-	-	-	-	-
				(1)	(1)												
Total non-operating income	36	(350)	-					-	-	-	-	-	-	-	-	-	-
Pretax Income	(11,138)	(8,048)	(9,126)	(19,518)	(6,635)	(2,323)	(2,415)	(30,891)	(12,000)	21,306	146,822	383,639	623,941	808,644	905,208	960,819	795,415
Income Tax Benefit (Provision)		-	-	-	-	-	-	-	(600)	2,131	20,555	69,055	137,267	185,988	217,250	240,205	206,808
Tax Rate									5%	10%	14%	18%	22%	23%	24%	25%	26%
GAAP Net Income (loss)	(11,281)	(8,048)	(9,126)	(19,518)	(6,635)	(2,323)	(2,415)	(30,891)	(11,400)	19,175	126,267	314,584	486,674	622,656	687,958	720,614	588,607
Preferred stock dividend	176.24	80.43	8.62	3,188	8.00												
Net and comprehensive loss available to common stockholders	(11,315)	(9,178)	(9,135)	(22,706)	(6,643)	(2,323)	(2,415)	(30,891)	(11,400)	19,175	126,267	314,584	486,674	622,656	687,958	720,614	588,607
GAAP-EPS	(0.55)	(1.28)	(0.87)	(1.33)	(0.23)	(0.08)	(0.08)	(1.72)	(0.39)	0.64	4.18	10.38	15.99	20.37	22.42	23.39	19.03
Non GAAP EPS (dil)	(0.55)	(0.87)	(0.87)	(1.33)	(0.23)	(0.08)	(0.08)	(1.71)	(0.34)	0.42	2.63	6.30	9.36	11.51	12.22	12.30	9.65
Wgtd Avg Shrs (Bas) - '000s	20,861	2,575	10,444	17,106	29,273	29,302	29,332	26,253	29,543	30,075	30,196	30,317	30,438	30,560	30,682	30,805	30,929
Wgtd Avg Shrs (Dil) - '000s	20,861	2,575	10,444	17,106	29,273	29,566	29,861	26,452	34,097	46,136	48,010	49,959	51,988	54,098	56,295	58,581	60,959

Source: Dawson James estimates for 2021E-2030E, company reports

Important Disclosures:

Price Chart:



Price target and ratings changes over the past three years:

Initiation - June 6, 2017 – Buy – Price target 20% (12-18 months)

Update – August 8, 2017 – Buy – Price target \$6.60

Update – March 1, 2018 – Buy - \$6.60

Transfer – July 11, 2019 - Buy - \$4.00

Update – July 15, 2019 – Buy \$4.00

Update – July 24, 2019 – Buy \$4.00

Update – July 31, 2019 – Buy \$4.00

Update – August 27, 2019 – Buy \$4.00

Update – September 18, 2019 – Buy \$4.00

Update – December 2, 2019 – Buy \$4.00

Update – February 14, 2020 – Buy \$4.00

Update – March 5, 2020 – Buy \$4.00

Update – May 5, 2020 – Buy \$4.00

Update – May 13, 2020 – Buy \$4.00

Update – June 4, 2020 – Buy \$4.00

Update – June 10, 2020 – Buy \$4.00

Update – June 23, 2020 – Buy \$4.00

Update – June 24, 2020 – Buy \$4.00

Update – July 30, 2020 – Buy \$4.00

Update – September 9, 2020 – Buy \$4.00

Update – November 23, 2020 – Buy \$4.00

Update – January 11, 2021 – Buy \$4.00

Update – January 21, 2021 – Buy \$4.00

Update – February 1, 2021 – Buy \$4.00

Update – February 25, 2021 – Buy \$5.00

Update – April 14, 2021 – Buy \$5.00

Update – May 18, 2021 – Buy \$5.00

Update – May 26, 2021 – Buy \$5.00

Update – July 1, 2021 – Buy \$5.00

Update – August 17, 2021 – Buy \$5.00

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

The Firm does not make a market in the securities of the subject Company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject Company(s). The Firm has received other compensation from the subject Company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the Company(s) in this report and may increase or decrease holdings in the future. As of July 31, 2021, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the Company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the “VALUATION” and “RISK ANALYSIS” sections of this report.

The securities of the Company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

As of: 3-Aug-21

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	25	71%	4	16%
Market Perform (Neutral)	10	29%	0	0%
Market Underperform (Sell)	0	0%	0	0%
Total	35	100%	4	11%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst

in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.